SCHEMBL4701494

SCHEMBL4701494

CC(C)(C)OC(=O)N1CC(=O)N(CCCO[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)c2ccccc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 7/20 0.41
HDAC1 Q13547 6/20 0.41
HDAC3 O15379 6/20 0.36
HDAC8 Q9BY41 5/20 0.36
NPSR1 Q6W5P4 2/20 0.35
SMYD2 Q9NRG4 1/20 0.34
DRD2 P14416 3/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HTR1A P08908 1/20 0.34
HTR2A P28223 1/20 0.34
DRD3 P35462 2/20 0.33
ALDH1A1 P00352 2/20 0.33
LMNA P02545 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
PKM P14618 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7139728 0.91 SMYD2 (0.36) HDAC6HDAC1HDAC3HDAC8NPSR1
SCHEMBL6006023 0.88 HDAC1 (0.43) HDAC6HDAC1HDAC3HDAC8NPSR1
SCHEMBL4698629 0.74 HDAC1 (0.46) HDAC6HDAC1ALDH1A1KMT2A
SCHEMBL4369237 0.71 HDAC1 (0.61) HDAC6HDAC1HDAC8DRD2HTR1A
SCHEMBL29888238 0.68 MEN1 (0.39) HDAC6HDAC1HDAC8SMYD2KDM4E
SCHEMBL20556261 0.68 GPR119 (0.43) KDM4EPKM
SCHEMBL20556625 0.68 GPR119 (0.43) KDM4EPKM
SCHEMBL12192745 0.67 SMYD2 (0.36) HDAC6HDAC1HDAC3HDAC8SMYD2
SCHEMBL14315531 0.67 SMYD2 (0.35) HDAC6HDAC1HDAC3HDAC8SMYD2
SCHEMBL29887855 0.66 SMYD2 (0.38) SMYD2KDM4EMEN1PKMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1326849-B1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE MERCK SHARP & DOHME (GB) 2008-07-16 EP disclosed
US-6995155-B2 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2006-02-07 US disclosed
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2004-02-05 US disclosed
EP-1326849-A1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE Merck Sharp & Dohme Limited (GB) 2003-07-16 EP disclosed
WO-2002030912-A1 BENZODIAZEPINE DERIVATIVES AS INHIBITORS OF GAMMA SECRETASE MERCK SHARP & DOHME LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024203-A1 Benzodiazepine derivatives as inhibitors of gamma secretase BACE1, BACE2, PSEN1 HDAC6 1236/4885HDAC1 452/4885HDAC3 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.